SCHEMBL22802457

SCHEMBL22802457

CC(C)(C)[Si](C)(C)OCc1cc(F)cc(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 7/20 0.41
IDO1 P14902 2/20 0.33
AGXT P21549 2/20 0.33
BACE1 P56817 1/20 0.32
ROCK2 O75116 1/20 0.31
ROCK1 Q13464 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29490396 1.00 RIPK1 (0.41) RIPK1IDO1AGXTBACE1ROCK2
SCHEMBL29490394 1.00 RIPK1 (0.41) RIPK1IDO1AGXTBACE1ROCK2
SCHEMBL31362543 0.80
SCHEMBL30976535 0.80 IDO1 (0.56) RIPK1IDO1AGXTBACE1
SCHEMBL27106193 0.80 IDO1 (0.56) RIPK1IDO1AGXTBACE1
SCHEMBL31490382 0.77 APLNR (0.31)
SCHEMBL3076782 0.77 BACE1 (0.40) RIPK1IDO1BACE1
SCHEMBL17864568 0.75 IDO1 (0.32) IDO1AGXTBACE1
SCHEMBL17083346 0.75 RIPK1 (0.45) RIPK1IDO1AGXT
SCHEMBL27106191 0.75 IDO1 (0.50) IDO1AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2026-03-05 US disclosed
EP-4299135-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-08-06 EP disclosed
US-12371425-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2025-07-29 US disclosed
EP-3986890-B9 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-04-16 EP disclosed
WO-2025007873-A1 KAT6 INHIBITOR 上海齐鲁制药研究中心有限公司 2025-01-09 WO disclosed
EP-4299135-A2 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2024-01-03 EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 EP disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 US disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 US disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 US disclosed
US-11492346-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2022-11-08 US disclosed
EP-3986890-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2022-04-27 EP disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 US disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 WO disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371425-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR RIPK1 3198/4885IDO1 4274/4885AGXT 2879/4885
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR RIPK1 3106/4885IDO1 4093/4885AGXT 2852/4885
US-11492346-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR RIPK1 3198/4885IDO1 4274/4885AGXT 2879/4885
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives KAT8, KAT5, KAT7 RIPK1 2990/4885IDO1 1350/4885AGXT 447/4885
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR RIPK1 3198/4885IDO1 4274/4885AGXT 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.